Tandem Diabetes Care is navigating a strategic pivot marked by gross margin recovery to 56.9% in 2026Q2, yet persistent net losses of -$21.2M and a debt-to-equity ratio of 5.67 signal strained financial flexibility. Revenue growth of 5.8% year-over-year remain...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.31+3.3% vs -$0.32 | $255M-0.2% vs $255M |
Q2 2026 May 7, 2026 | -$0.30+34.8% vs -$0.46 | $247M+2.8% vs $240M |
Q1 2026 Feb 19, 2026 | -$0.01+80.0% vs -$0.05 | $290M+4.8% vs $277M |
Q4 2025 Nov 6, 2025 | -$0.31+0.0% vs -$0.31 | $249M+5.7% vs $236M |
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
On September 10, 2026, Tandem Diabetes Care Inc (TNDM) shares fell 4.2% to a current price of $18.31. The stock has experienced notable volatility, trading betw
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
Benchmark TNDM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tandem Diabetes Care, Inc. (TNDM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.50 | $1.2B | -5.76 | 7.93% | -20.17% | -97.88% | — | |
| $139.38 | $9.65B | 40.05 | 30.73% | 12.29% | 26.69% | — | |
| $89.53 | $34.55B | 42.84 | 15.6% | 20.12% | 36.19% | — | |
| $265.32 | $468.77B | 111.95 | 8.57% | 9.81% | — | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — | |
| $39.40 | $174.96B | 11.15 | 6.43% | 35.35% | 59.09% | — |
Tandem Diabetes Care, Inc. (TNDM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tandem Diabetes Care, Inc. (TNDM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 21, 2026·SEC
May 15, 2026·SEC
Get notified when TNDM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tandem Diabetes Care, Inc. (TNDM) stock FAQ — growth, dividends, profitability & financials explained
Tandem Diabetes Care, Inc. (TNDM) reported $1.04B in revenue for fiscal year 2025.
Tandem Diabetes Care, Inc. (TNDM) grew revenue by 7.9% over the past year. This is steady growth.
Tandem Diabetes Care, Inc. (TNDM) reported a net loss of $63.3M for fiscal year 2025.
Tandem Diabetes Care, Inc. (TNDM) has a return on equity (ROE) of -97.9%. Negative ROE indicates the company is unprofitable.
Tandem Diabetes Care, Inc. (TNDM) had negative free cash flow of $26.6M in fiscal year 2025, likely due to heavy capital investments.
